Integration of a Molecular Prognostic Classifier into the Ninth Edition TNM Staging of Lung Adenocarcinoma

IntroductionDespite advancements in non-small cell lung cancer (NSCLC) management through the use of molecular biomarkers, the recently introduced 9th edition of the TNM staging system remains based exclusively on anatomic descriptors, with no consistently demonstrated improvement in risk stratification for early-stage disease. This study explores the integration of a molecular prognostic classifier into the conventional TNM staging system. MethodsWe analyzed 502 patients with stage I-III lung adenocarcinoma (LUAD) who underwent surgical resection with tumor-based gene expression profiling at the Quebec Heart and Lung Institute. A molecular prognostic classifier was developed and integrated into the 9th edition TNM staging system to generate a novel model (TNMEx). Prognostic performance was compared with the 8th and 9th TNM editions using prognostic discrimination and reclassification metrics. External validation of the molecular classifier was performed in 271 LUAD cases from The Cancer Genome Atlas (TCGA). An independent cohort of 606 resected LUAD patients from the National Cancer Center Hospital (Tokyo) was used to externally compare the prognostic performance of the 8th and 9th TNM staging systems in the absence of molecular data. ResultsThe molecular prognostic classifier was developed based on the expression levels of 26 prognosis-associated genes, weighted by their corresponding coefficients. The classifier was subsequently integrated into the 9th edition TNM staging to generate the TNMEx model. The TNMEx system demonstrated superior prognostic performance, achieving a higher concordance index (C-index = 0.72) compared to the 9th edition TNM (C-index = 0.65, p=0.006). Moreover, TNMEx significantly improved patient risk reclassification compared to both the 8th (net reclassification improvement [NRI] = 0.27, integrated discrimination improvement [IDI] = 0.04) and 9th editions (NRI = 0.40, IDI = 0.05), underscoring its superior ability to stratify outcomes. The 8th and 9th editions showed only limited improvement in overall prognostic accuracy and risk stratification, as reflected by their relatively modest C-index values (0.62 and 0.65, respectively) and minimal reclassification gains (NRI = -0.06, IDI = 0.003). ConclusionsIncorporating a molecular-based prognostic model significantly enhanced the ability to recognize patients at high risk and to predict their survival outcomes more accurately than traditional TNM staging systems.